Scineuro Pharmaceuticals secured a $5 million Michael J. Fox Foundation grant to accelerate preclinical development of SNP‑614, an LRRK2‑targeting antisense oligonucleotide for Parkinson’s disease. The funding supports IND‑enabling studies and signals investor and foundation confidence in nucleic‑acid approaches targeting genetic drivers such as LRRK2. The grant will help Scineuro de‑risk translational steps, optimize dosing and advance toxicology work required for first‑in‑human studies. The award highlights growing philanthropic and non‑dilutive backing for genetic medicines in neurodegeneration.